Clinical Competition Candidate
BRISDELLE
BRISDELLE carries substance and product and use-code patents, moderate complexity (2/5), and meaningful clinical competition (4/5). The listed expiry window is approximately 33 months away. Active clinical competition may compress the generic entry window.
LOE window
33months
to latest listed patent expiry (April 6, 2029)
Expiry attractiveness: 5/5
Patent profile
Substance patent (listed)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 3
Complexity score: 2/5
Clinical competition
Score: 4/5
Active trials linked: 307
Phase 2/3 trials: 91
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: PAROXETINE MESYLATE
Applicant (NDA holder): LEGACY PHARMA INC SEZC
Confidence: High